In January 2021, a little more than a month after the first COVID-19 vaccines received emergency use authorisation, the directors of America's leading public-health agencies exchanged messages about pregnant women. The texts, recovered years later from Anthony Fauci's government-issued phone and released by Senators Ron Johnson and Rand Paul, do not describe a completed safety file. They describe a conversation among people who already knew the pivotal trials had left a gap.
Pregnant women had been excluded from the original Pfizer and Moderna randomised trials. That exclusion was standard practice for new pharmaceuticals, but it left the first large-scale use of the products in pregnancy without the kind of controlled evidence that normally precedes a recommendation. Dr. Peter McCullough has repeatedly made this point: because those women were kept out of the initial studies, the shots were administered to expectant mothers without direct trial proof that they did not raise the risk of miscarriage. The texts now show that senior officials were discussing exactly that uncertainty in private while public messaging moved toward reassurance.
On 25 January 2021, incoming Surgeon General Vivek Murthy asked Fauci and CDC Director Rochelle Walensky whether there was any reason to prefer vaccination early or late in pregnancy. Walensky replied that her understanding was the question was "data free." Fauci initially agreed there was "no data or theoretical reason" to favour one timing over another. Then John Mascola, director of NIAID's Vaccine Research Center, corrected the record in a message to Fauci: initial studies had avoided vaccination in the first trimester "due to possible fever and higher rates of miscarriage in first trimester." Within minutes Fauci forwarded the implication to Murthy and Walensky: because many people experience a significant cytokine response and fever after the second dose, "this theoretically could be associated with miscarriage in the first trimester." Walensky called it "a good point, especially after dose two."
The language is cautious: "theoretically could," yet it is not the language of officials who regarded the matter as settled. Fauci later added that officials must weigh potential risks against benefits because COVID-19 itself can be serious in pregnancy, and that more than 10,000 pregnant women had already been vaccinated with no issues reported at that snapshot in time. Those two sentences sit side by side in the same exchange: a theoretical first-trimester concern tied to fever, and an early observational count offered as reassurance. What the public heard in the weeks that followed leaned heavily toward the second sentence. Fauci told interviewers there were "no red flags." Recommendations to vaccinate pregnant women hardened.
McCullough's critique follows directly from the trial design and from this sequence. If the randomised studies never enrolled pregnant participants, then claims of proven safety regarding miscarriage rest on later observational registries and cohort studies, not on the gold-standard evidence that was missing at the moment of rollout. He has described the products as untested in this population for that outcome and has argued they should have been treated as contraindicated until adequate data existed. Subsequent large analyses have generally reported miscarriage rates within expected background ranges, but those studies remain observational, subject to confounding, and often incomplete for the earliest weeks of pregnancy, the period Mascola and Fauci flagged. Critics of the official narrative, including McCullough, treat that later literature as insufficient to close the original gap.
The texts do not prove that officials knew the vaccines caused miscarriages and hid a finished dataset. They do show that the possibility of first-trimester harm from a febrile immune response was raised at the highest level, that the initial studies had deliberately avoided that window, and that the theoretical concern was not the message delivered to the public. Informed consent requires that patients hear both the known benefits and the acknowledged uncertainties. In January 2021 the uncertainties were still live inside the agencies. The recommendations went out anyway.
That is the record the Johnson-Paul release placed on the table. Pregnant women were asked to accept a novel product whose pivotal trials had excluded them, while the officials overseeing the campaign privately noted a mechanism, fever and cytokine response, that could, in theory, raise miscarriage risk in the first trimester. Whether later observational data fully answers that concern remains contested. What is no longer contested is that the concern itself was discussed at the top before the public was told the question had been resolved.
https://www.thefocalpoints.com/p/clearer-exposition-of-how-drs-fauci